NCT05082636View on ClinicalTrials.gov

The Role of Programmed Death Ligand -1 (Pdl-1) in Lung Cancer

CompletedOBSERVATIONAL
Enrollment

90

Participants

Timeline

Start Date

June 15, 2018

Primary Completion Date

June 20, 2020

Study Completion Date

March 25, 2021

Conditions
Lung Cancer
Interventions
OTHER

Observational Study ( Tissue Biopsy )

control study includes a total of 90 subjects. Of them 54 patients with early stage lung (stage I, II) cancer (Group 1) were selected from the Chest Department of Assiut University Hospital, besides 36 healthy controls; who were clinically suspicious with chest masses and proven histopathologically to be negative cancer (Group 2).obtained by fiberoptic bronchoscopy

Trial Locations (1)

71515

Assiut University, Asyut

All Listed Sponsors
lead

Assiut University

OTHER

NCT05082636 - The Role of Programmed Death Ligand -1 (Pdl-1) in Lung Cancer | Biotech Hunter | Biotech Hunter